Cardiology – Page 35

Linking Retinal Microvasculature to Silent Coronary Atherosclerosis: Insights from Optical Coherence Tomography Angiography

By MedXY 09/27/2025

Reduced retinal parafoveal vascular density measured by OCTA independently correlates with subclinical coronary atherosclerosis, revealing a novel noninvasive biomarker for cardiovascular risk assessment beyond traditional factors.

Cardiology Clinical Updates Neurology news

Electrophysiological Study Surpasses ECG in Predicting Life-Threatening Conduction Delays in Myotonic Dystrophy Type 1

By MedXY 09/27/2025

In patients with myotonic dystrophy type 1 (DM1), electrophysiological study (EPS) using the His-ventricular (HV) interval is superior to electrocardiogram (ECG) in predicting major bradyarrhythmic events, suggesting enhanced risk stratification with EPS-guided thresholds.

Cardiology Clinical Updates news

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Cardiology Internal Medicine

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY 09/26/2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effective as full dose but lowers bleeding risk.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Cardiology Clinical Updates news

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

By MedXY 09/24/2025

This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.

Cardiology Clinical Updates

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

By MedXY 09/23/2025

The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increased coronary events in the aspirin-free group.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Cardiology Clinical Updates news Specialties

Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis

By MedXY 09/22/2025

In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.

Cardiology Clinical Updates Radiology

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

By MedXY 09/22/2025

A multicenter trial shows cardiac MRI offers comparable sensitivity to invasive coronary angiography for diagnosing ischemic cardiomyopathy, reducing invasive procedures in newly diagnosed heart failure patients.

Cardiology Clinical Updates Critical Care news Specialties

Advanced Airway Devices and End-Tidal CO2 Trends in Cardiac Arrest: Insights from a Multicenter Randomized Trial

By MedXY 09/22/2025

This analysis compares end-tidal CO2 trends between laryngeal tube and endotracheal intubation in out-of-hospital cardiac arrest, revealing no significant difference in absolute values but highlighting complex interactions affecting return of spontaneous circulation outcomes.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Cardiology Clinical Updates news

Intravascular Imaging-Guided PCI vs CABG for Left Main or 3-Vessel Disease: Bridging the Outcome Gap

By MedXY 09/22/2025

Recent study shows intravascular imaging-guided PCI may offer comparable 3-year outcomes to CABG in patients with left main or 3-vessel coronary disease, challenging prior assumptions favoring surgery.

Cardiology Clinical Updates Neurology news Specialties

Impact of Hypertension History on the Efficacy of Clopidogrel-Aspirin Therapy in Ischemic Stroke Prevention

By MedXY 09/22/2025

This study investigates how a history of hypertension influences the effectiveness of combined clopidogrel-aspirin treatment in preventing recurrent strokes after mild ischemic events or high-risk transient ischemic attacks.

Cardiology Clinical Updates news Specialties

DIALIZE-Outcomes Trial: Sodium Zirconium Cyclosilicate Effect on Cardiovascular Outcomes in Hemodialysis Patients with Hyperkalemia

By MedXY 09/22/2025

The DIALIZE-Outcomes trial assessed sodium zirconium cyclosilicate (SZC) in controlling predialysis hyperkalemia among hemodialysis patients but found no reduction in arrhythmia-related cardiovascular events despite improved potassium control.

Cardiology Clinical Updates news Specialties

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY 09/22/2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Cardiology news Specialties

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial

By MedXY 09/21/2025

The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.

Cardiology news Specialties

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

By MedXY 09/21/2025

The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.

Cardiology Clinical Updates news

Comparing the PREVENT and PCE Models for 10-Year ASCVD Risk Prediction: Insights from a Large Real-World Cohort

By MedXY 09/20/2025

This review evaluates PREVENT versus PCE models for estimating 10-year ASCVD risk focusing on accuracy in patients with and without statin therapy, highlighting implications for personalized prevention.